Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL-Reference-Cited by-同舟云学术

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL

Published:2016-10 Issue:8 Volume:39 Page:321-328
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Engelstein Roni,Merims Sharon,Eisenberg Galit,Cohen Jonathan,Frank Stephen,Hamburger Tamar,Frankenburg Shoshana,Ron Ilan,Isacson Ruth,Grenader Tal,Steinberg Hanna,Cohen Cyrille J.,Peretz Tamar,Lotem Michal

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference38 articles.

1. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684;Kirkwood;J Clin Oncol,1996

2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

3. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

4. Combination cancer immunotherapy and new immunomodulatory targets;Mahoney;Nat Rev Drug Discov,2015

5. PD-1 blockade induces responses by inhibiting adaptive immune resistance;Tumeh;Nature,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments;Frontiers in Immunology;2021-02-17

2. Extracellular vesicles produced by immunomodulatory cells harboring OX40 ligand and 4-1BB ligand enhance antitumor immunity;Scientific Reports;2020-09-16

3. Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study;Frontiers in Oncology;2020-02-14

4. Combination of pentoxifylline and α-galactosylceramide with radiotherapy promotes necro-apoptosis and leukocyte infiltration and reduces the mitosis rate in murine melanoma;Acta Histochemica;2019-08

5. T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer;Advanced Drug Delivery Reviews;2019-02